Showing 1961-1970 of 5627 results for "".
- Yale Study Uncovers How Brain Wiring Begins Before Birthhttps://modernod.com/news/yale-study-uncovers-how-brain-wiring-begins-before-birth/2482409/Researchers at Yale say they have uncovered how the brain begins to wire itself during early development, long before experiences or sensory inputs like sight come into play. The study, published this month in Science, reveals that brain cells start forming networks based on sp
- EyeSouth Partners Affiliates With Community Eye Care Specialists in New Yorkhttps://modernod.com/news/eyesouth-partners-affiliates-with-community-eye-care-specialists-in-new-york/2482233/EyeSouth Partners announced it has partnered with Community Eye Care Specialists, representing its first affiliation in New York, third affiliation in Pennsylvania. and 40th affiliation overall. Financial terms of the deal were not disclosed. EyeSouth is an eye care-focused ma
- Genentech and Nvidia Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Developmenthttps://modernod.com/news/genentech-and-nvidia-enter-into-strategic-ai-research-collaboration-to-accelerate-drug-discovery-and-development/2481979/In a move aimed at speeding up drug discovery and development, Genentech announced a multi-year strategic research collaboration with Nvidia. Financial terms of the deal were not disclosed. The partnership will combine Genentech’s artificial intelligence
- Two-Year Results of Eylea HD (Aflibercept 8 mg) from PULSAR Trial for Wet AMD Presented at Euretinahttps://modernod.com/news/two-year-results-of-eylea-hd-aflibercept-8-mg-from-pulsar-trial-presented-at-euretina/2481870/Regeneron announced the first presentation of positive 2-year (96 weeks) results from the PULSAR trial investigating Eylea HD (aflibercept) injection 8 mg with 12- and 16-week dosing regimens, compared to Eylea (aflibercept) injection, in patients with wet age-related macular degenerati
- Sight Sciences Announces New MIGS Data Demonstrating TCOR Using OMNI Surgical System Lowers IOP and Medication Use at 2 Yearshttps://modernod.com/news/sight-sciences-announces-new-migs-data-demonstrating-tcor-using-omni-surgical-system-lowers-iop-and-iop-reducing-medications-at-2-years/2481863/Sight Sciences announced the results of the large scale, comparative real-world clinical outcomes study of patients treated by three leading minimally invasive glaucoma surgery (MIGS) technologies, which were recently presented at the 41st Congress of the European Society of Cataract an
- Regeneron Presents 2-Year PULSAR Trial Results for Aflibercept 8 MG in Wet AMDhttps://modernod.com/news/regeneron-presents-2-year-pulsar-trial-results-for-aflibercept-8-mg-in-wet-amd/2481772/Regeneron announced positive, 2-year (96 weeks), topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular degeneration (AMD). During the trial, aflibercept 8 mg patients were initially randomized to either 12- or 16-week dosing interv
- Ciliatech Presents 2-Year Postoperative Results on New Cilio-Scleral Surgical Approach for Treating Glaucomahttps://modernod.com/news/ciliatech-presents-2-year-postoperative-results-on-new-cilio-scleral-surgical-approach-for-treating-glaucoma/2481698/Ciliatech announced it will present the preliminary results of the second 2-year postoperative clinical trial (SAFARI II) on its Cilia-scleral Interposition Device (CID) during the World Glaucoma Congress, taking place this week. Ciliatech will present results showing sta
- Cellusion Raises $21 Million to Advance iPS Cell-Derived Corneal Endothelial Cell Substitutehttps://modernod.com/news/cellusion-raises-21-million-to-advance-ips-cell-derived-corneal-endothelial-cell-substitute/2481659/Tokyo-based Cellusion announced that it has raised 2.83 billion yen ($21 million USD) in Series C Round financing. The funding will be used to promote its lead program—the development of iPS cell-derived corneal endothelial cell substitute (CLS001) to resolve the challenge of
- AI-based Systems Can Help Identify Rapidly Advancing Age-Related Macular Degenerationhttps://modernod.com/news/ai-based-systems-can-help-identify-rapidly-advancing-age-related-macular-degeneration/2481490/Researchers supported by the National Eye Institute (NEI) are developing artificial intelligence/machine learning (AI/ML)-based systems that not only screen for AMD but also predict which patients will likely progress to late within 2 years,
- Bausch + Lomb Launches Social Media Campaign Designed to Raise Awareness of AMDhttps://modernod.com/news/bausch-lomb-launches-social-media-campaign-designed-to-raise-awareness-of-amd/2481393/Bausch + Lomb announced a new social media campaign designed to raise awareness of age-related macular degeneration (AMD). The campaign, "What Sight Inspires You," will feature personal stories and sights from Bausch + Lomb’s SightMatters community, an online educat